Efficacy And Safety Of Sodium-Glucose Cotransporter-2 (Sglt2) And Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Combination Therapy In Patients With Type 2 Diabetes Inadequately Controlled By Metformin

Darshan  Kumar; Shaheen  Bhatty; Syed Muhammad Kashif; Pawan Kumar

doi:10.51253/pafmj.v76i2.12228

Authors

Darshan Kumar Department of Medicine, DIMC / Dow University Hospital Ojha Campus, Dow University of Health Sciences Karachi Pakistan
Shaheen Bhatty Department of Medicine, DMC/ Dr. Ruth K.M. Pfau Civil Hospital, Dow University of Health Sciences Karachi Pakistan
Syed Muhammad Kashif Department of Medicine, DMC/ Dr. Ruth K.M. Pfau Civil Hospital, Dow University of Health Sciences Karachi Pakistan
Pawan Kumar Department of Medicine, DIMC / Dow University Hospital Ojha Campus, Dow University of Health Sciences Karachi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76i2.12228

Keywords:

DPP4 Inhibitors; Glycaemic Control; Lipid Profiles; Metformin; Renal Function; SGLT2 Inhibitors; Type 2 Diabetes

Abstract

Objective: To evaluate the effectiveness and safety of combining SGLT2 inhibitors with or without DPP4 inhibitors as an add-on therapy for type 2 diabetes patients.

Study Design: Quasi-Experimental Study

Place and Duration of Study: Dr. Ruth KM Pfau Civil Hospital and Dow University Hospital Ojha Campus, Dow University of Health Sciences, Karachi, Pakistan, from Mar 21 to Dec 23.

Methodology: The study assessed type 2 diabetes patients on Metformin alone with an HbA1c level exceeding 7% and evaluated various clinical and biochemical markers.

Results: In a study of 239 obese and poorly controlled diabetic patients, 58.58% were female, and 41.42% were male, with an age range of 40-60 years. Diabetes duration was below 5 years in 17.57% of patients, between 5 and 10 years in 44.45%, and over 10 years in 38.07%. The treatment groups were as follows: Metformin + SGLT2 inhibitors (27.00%), Metformin + DPP4 inhibitors (32.00%), and all three combinations (41.00%). During a span of 36 weeks, a significant difference was seen in the levels of HbA1c (p < 0.001). Moreover, the BMI of male subjects. In addition, there were significant decreases in FBS, RBS, and triglyceride levels, whereas creatinine levels did not change.

Conclusion: Metformin, when combined with SGLT2 and DPP4 inhibitors, improves glycaemic control and weight reduction in morbid obesity patients, especially in males, with significant changes in HbA1c, fasting, and postprandial glucose levels.

Downloads

Download data is not yet available.

References

1. Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev 2016; 37(3): 278-316. https://doi.org/10.1210/er.2015-1137

2. Shubrook JH, Chen W, Lim A. Evidence for the prevention of type 2 diabetes mellitus. J Am Osteopath Assoc 2018; 118(11): 730-737.

https://doi.org/10.7556/jaoa.2018.158

3. Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: a review on recent drug-based therapeutics. Biomed Pharmacother 2020; 131: 110708.

https://doi.org/10.1016/j.biopha.2020.110708

4. Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or Metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2016; 164(11): 740-751.

https://doi.org/10.7326/M15-2650

5. Melzer Cohen C, Davis C, Shalev V, Chodick G. Effectiveness of vildagliptin as add-on to Metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting. J Diabetes 2018; 10(1): 68-72.

https://doi.org/10.1111/1753-0407.12560

6. Wang Z, Sun J, Han R, et al. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to Metformin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab 2018; 20(1): 113-120.

https://doi.org/10.1111/dom.13047

7. Zhou Y, Geng Z, Wang X, Huang Y, Shen L, Wang Y. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to Metformin in type 2 diabetes. Diabetes Metab Res Rev 2020; 36(2): e3223.

https://doi.org/10.1002/dmrr.3223

8. Singh AK, Singh R, Khunti K. Comment on Gan et al. Efficacy of modern diabetes treatments DPP-4i, SGLT-2i, and GLP-1RA in white and Asian patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care 2020; 43(12): e200-e201.

https://doi.org/10.2337/dc20-1950

9. Hagi K, Kochi K, Watada H, Kaku K, Ueki K. Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of two randomized, placebo-controlled trials. J Diabetes Investig 2023; 14(9): 1101-1109.

https://doi.org/10.1111/jdi.14035.

10. Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity 2022; 55(1): 31-55.

https://doi.org/10.1016/j.immuni.2021.12.013

11. Dutta D, Jaisani R, Khandelwal D, Ghosh S, Malhotra R, Kalra S. Role of Metformin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and orlistat based multidrug therapy in glycemic control, weight loss, and euglycemia in diabesity: a real-world experience. Indian J Endocrinol Metab 2019; 23(4): 460-467.

https://doi.org/10.4103/ijem.IJEM_185_19

12. Gilbert MP, Pratley RE. GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials. Front Endocrinol 2020; 11: 178.

https://doi.org/10.3389/fendo.2020.00178

13. Shaheer A, Kumar A, Menon P, Jallo M, Basha S. Effect of add-on therapy of sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on adipokines in type 2 diabetes mellitus. J Clin Med Res 2021; 13(6): 355-362.

https://doi.org/10.14740/jocmr4510

14. Min SH, Yoon JH, Moon SJ, Hahn S, Cho YM. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis. Sci Rep 2018; 8(1): 4466.

https://doi.org/10.1038/s41598-018-22658-2

15. Bashier A, Khalifa AA, Rashid F, et al. Efficacy and safety of SGLT2 inhibitors in reducing glycated hemoglobin and weight in Emirati patients with type 2 diabetes. J Clin Med Res 2017; 9(6): 499-507.

https://doi.org/10.14740/jocmr2976w

16. Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2017; 24(1): 73-79. https://doi.org/10.1097/MED.0000000000000311

17. Xu B, Li S, Kang B, Zhou J. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc Diabetol 2022; 21(1): 83.

https://doi.org/10.1186/s12933-022-01512-w